Doxorubicin Hcl (Doxorubicin Hcl)
Overview of Doxorubicin Hcl
Doxorubicin Hcl/Adriamycin HCl is antineoplastic agent, also called as anticancerous drug. Doxorubicin Hcl is the prototype agent of anthracycline antibiotic, isolated from Streptomyces peucetius var caesius. It contains an amino sugar and an anthracycline ring. Doxorubicin Hcl is among the most useful cytotoxic anticancerous drugs. It has a broad spectrum of potent activity against many different types of cancers specially haematologic malagnancies. Doxorubicin Hcl is used in combination with different anticancerous drugs to obtain best therapeutic effects and to reduce the side effects or toxcities.
Indication of Doxorubicin Hcl
Indications
Contraindication of Doxorubicin Hcl
Doxorubicin (HCl) is contraindicated in conditions like Cardiac arrhythmia,Pregnancy,Breast feeding.
Side Effects of Doxorubicin Hcl
The severe or irreversible adverse effects of Doxorubicin (HCl), which give rise to further complications include Radiosensitization, Recall phenomenon.,Doxorubicin (HCl) produces potentially life-threatening effects which include Bone marrow suppression, Cardiotoxicity. which are responsible for the discontinuation of Doxorubicin (HCl) therapy.,The signs and symptoms that are produced after the acute overdosage of Doxorubicin (HCl) include Mucositis, Acute cardiac damage.,The symptomatic adverse reactions produced by Doxorubicin (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Alopecia, Anorexia, Diarrhea, Urticaria, Oral ulceration, Esophagitis, Lacrimation, Conjunctivitis, Local hypothermia, Alopecia, Hyperpigmentation of nails.
Precautions of Doxorubicin Hcl
Doxorubicin should be used with caution in patients who have had previous myelosuppressive therapy such as chemotherapy or radiation therapy, in patients with tumor infiltrate of the bone,with hepatic disease, in patients with dental disease. Dental work should be performed prior to initiating doxorubicin therapy, or deferred until blood counts return to normal. It should be usedwith extreme caution in patients with cardiac disease. Patients with active infection should betreated prior to receiving doxorubicin, the dose should be reduced or discontinued in patients whodevelop such infections. Patients should be observed closely for signs of cardiotoxicity; early recognition is essential for successful treatment of doxorubicin-induced cardiac toxicity. A reduction in dosage and/or dosage interval is indicated in patients with moderate to severe stomatitis. Doxorubicin therapy should not be initiated until patients recover normal hematopoiesis after bone marrow depression. Patients with pre-existing heart failure, with angina, or with cardiac arrhythmias are not good candidates to receive doxorubicin. It should not be administered during pregnancy and lactation.